RS58255B1 - Ciljana modifikacija genoma pacova - Google Patents

Ciljana modifikacija genoma pacova

Info

Publication number
RS58255B1
RS58255B1 RS20181446A RSP20181446A RS58255B1 RS 58255 B1 RS58255 B1 RS 58255B1 RS 20181446 A RS20181446 A RS 20181446A RS P20181446 A RSP20181446 A RS P20181446A RS 58255 B1 RS58255 B1 RS 58255B1
Authority
RS
Serbia
Prior art keywords
targeted modification
rat genome
genome
rat
targeted
Prior art date
Application number
RS20181446A
Other languages
English (en)
Inventor
Jeffrey D Lee
Alexander O Mujica
Wojtek Auerbach
Ka-Man Venus Lai
David M Valenzuela
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of RS58255B1 publication Critical patent/RS58255B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RS20181446A 2013-04-16 2014-04-16 Ciljana modifikacija genoma pacova RS58255B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361812319P 2013-04-16 2013-04-16
US201361914768P 2013-12-11 2013-12-11
EP14784879.0A EP2986729B1 (en) 2013-04-16 2014-04-16 Targeted modification of rat genome
PCT/US2014/034412 WO2014172489A2 (en) 2013-04-16 2014-04-16 Targeted modification of rat genome

Publications (1)

Publication Number Publication Date
RS58255B1 true RS58255B1 (sr) 2019-03-29

Family

ID=51687240

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20211065A RS62263B1 (sr) 2013-04-16 2014-04-16 Ciljana modifikacija genoma pacova
RS20181446A RS58255B1 (sr) 2013-04-16 2014-04-16 Ciljana modifikacija genoma pacova

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20211065A RS62263B1 (sr) 2013-04-16 2014-04-16 Ciljana modifikacija genoma pacova

Country Status (25)

Country Link
US (5) US20140310828A1 (sr)
EP (2) EP3456831B1 (sr)
JP (1) JP6411463B2 (sr)
KR (2) KR20200136508A (sr)
CN (2) CN105308184B (sr)
AU (2) AU2014253942B9 (sr)
BR (1) BR112015026197B1 (sr)
CA (1) CA2908697C (sr)
CY (2) CY1120845T1 (sr)
DK (2) DK2986729T3 (sr)
ES (2) ES2699578T3 (sr)
HK (1) HK1214625A1 (sr)
HR (2) HRP20181648T1 (sr)
HU (2) HUE056903T2 (sr)
IL (2) IL241856B (sr)
LT (2) LT2986729T (sr)
MX (1) MX369747B (sr)
MY (1) MY177850A (sr)
PL (2) PL3456831T3 (sr)
PT (2) PT2986729T (sr)
RS (2) RS62263B1 (sr)
RU (1) RU2676708C2 (sr)
SG (2) SG11201508028QA (sr)
SI (2) SI2986729T1 (sr)
WO (1) WO2014172489A2 (sr)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
CN109536526B (zh) * 2012-04-25 2020-06-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
UA118014C2 (uk) 2012-05-25 2018-11-12 Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія Спосіб модифікації днк-мішені
IL300199A (en) 2012-12-06 2023-03-01 Sigma Aldrich Co Llc CRISPR-based genome modification and regulation
ES2904803T3 (es) 2013-02-20 2022-04-06 Regeneron Pharma Modificación genética de ratas
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CA3161835A1 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
ES2699578T3 (es) 2013-04-16 2019-02-11 Regeneron Pharma Modificación direccionada del genoma de rata
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US9663782B2 (en) * 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
US9554564B2 (en) 2013-08-07 2017-01-31 Regeneron Pharmaceuticals, Inc. IncRNA-knockout mice
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150079680A1 (en) * 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
CN111218447A (zh) 2013-11-07 2020-06-02 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
PT3080279T (pt) * 2013-12-11 2018-12-17 Regeneron Pharma Métodos e composições para a modificação direcionada de um genoma
KR102170502B1 (ko) * 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN106413394B (zh) 2014-05-30 2020-02-11 再生元制药公司 人源化二肽基肽酶iv(dpp4)动物
LT3152312T (lt) 2014-06-06 2020-04-27 Regeneron Pharmaceuticals, Inc. Tikslinio lokuso modifikavimo būdai ir kompozicijos
JP6784601B2 (ja) 2014-06-23 2020-11-11 ザ ジェネラル ホスピタル コーポレイション シークエンシングによって評価されるゲノムワイドでバイアスのないＤＳＢの同定（ＧＵＩＤＥ−Ｓｅｑ）
PL3161128T3 (pl) 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do celowanych modyfikacji genetycznych i sposoby zastosowania
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
AU2015332451A1 (en) 2014-10-15 2017-04-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
US10457960B2 (en) 2014-11-21 2019-10-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
MX2017007636A (es) 2014-12-09 2018-03-28 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
MX2017008190A (es) * 2014-12-19 2018-03-23 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
US11208638B2 (en) 2015-01-12 2021-12-28 The Regents Of The University Of California Heterodimeric Cas9 and methods of use thereof
US11180792B2 (en) 2015-01-28 2021-11-23 The Regents Of The University Of California Methods and compositions for labeling a single-stranded target nucleic acid
US10202589B2 (en) 2015-03-03 2019-02-12 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
BR112017019620A2 (pt) 2015-03-16 2018-05-15 Regeneron Pharmaceuticals, Inc. ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor?
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
AU2016246450B2 (en) 2015-04-06 2022-03-17 Agilent Technologies, Inc. Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation
AU2016270587B2 (en) 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
EP3303634B1 (en) 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN114875012A (zh) 2015-08-28 2022-08-09 通用医疗公司 工程化的CRISPR-Cas9核酸酶
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN108135151A (zh) 2015-09-02 2018-06-08 瑞泽恩制药公司 前列腺癌的啮齿动物模型
CN105177110A (zh) * 2015-09-11 2015-12-23 中国科学院微生物研究所 核酸的检测方法
JP2018530536A (ja) 2015-09-11 2018-10-18 ザ ジェネラル ホスピタル コーポレイション ヌクレアーゼＤＳＢの完全照合およびシーケンシング（ＦＩＮＤ−ｓｅｑ）
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
KR20180053748A (ko) 2015-09-30 2018-05-23 더 제너럴 하스피탈 코포레이션 시퀀싱(circle-seq)에 의한 절단 반응의 포괄적인 시험관내 보고
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
NZ742447A (en) 2015-11-20 2022-12-23 Regeneron Pharma Non-human animals having a humanized lymphocyte-activation gene 3
EP3417061B1 (en) 2016-02-18 2022-10-26 The Regents of the University of California Methods and compositions for gene editing in stem cells
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
EP3429567B1 (en) 2016-03-16 2024-01-10 The J. David Gladstone Institutes Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
EP3457840B1 (en) * 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US20210010022A1 (en) * 2016-05-27 2021-01-14 Cambridge Enterprise Limited Novel nucleic acid construct
WO2017210586A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
JP2019523009A (ja) 2016-07-29 2019-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11279948B2 (en) 2016-08-31 2022-03-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric OX40
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
JP7026678B2 (ja) 2016-09-30 2022-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ９ｏｒｆ７２座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物
KR20230170126A (ko) 2016-09-30 2023-12-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
US10669539B2 (en) 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018112282A1 (en) 2016-12-14 2018-06-21 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
SG11201906540WA (en) 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2018152120A1 (en) 2017-02-14 2018-08-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
CA3053386A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CN108467873B (zh) * 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
CN106987604B (zh) * 2017-03-29 2021-05-28 北京希诺谷生物科技有限公司 一种制备动脉粥样硬化疾病模型犬的方法
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3630849A4 (en) 2017-05-25 2021-01-13 The General Hospital Corporation BIPARTITE BASIC EDITOR (BBE) AND TYPE II-C-CAS9 ZINC FINGER EDITOR ARCHITECTURES
CN109136273B (zh) * 2017-06-16 2022-09-27 中国科学院分子细胞科学卓越创新中心 制备免疫缺陷的大鼠的方法及其应用
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
BR112020001364A2 (pt) 2017-07-31 2020-08-11 Regeneron Pharmaceuticals, Inc. métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
US11021719B2 (en) 2017-07-31 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
JP2020532967A (ja) 2017-08-23 2020-11-19 ザ ジェネラル ホスピタル コーポレイション 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3679143A1 (en) * 2017-09-08 2020-07-15 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
SG11202002130WA (en) * 2017-09-28 2020-04-29 Toolgen Inc Artificial genome manipulation for gene expression regulation
US11572574B2 (en) 2017-09-28 2023-02-07 Toolgen Incorporated Artificial genome manipulation for gene expression regulation
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
PT3687287T (pt) 2017-09-29 2023-11-03 Regeneron Pharma Roedores que expressam complexo c1q humanizado
JP2021500864A (ja) * 2017-09-29 2021-01-14 インテリア セラピューティクス，インコーポレイテッド Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
WO2019075197A1 (en) 2017-10-11 2019-04-18 The General Hospital Corporation METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
EP3697906A1 (en) 2017-10-16 2020-08-26 The Broad Institute, Inc. Uses of adenosine base editors
CA3076377A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
PL3720279T3 (pl) 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
JP7334178B2 (ja) 2018-03-19 2023-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＣＲＩＳＰＲ／Ｃａｓ系を使用した動物での転写モジュレーション
CN116514959A (zh) 2018-03-24 2023-08-01 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
EP3775229A4 (en) * 2018-03-27 2021-12-15 The Trustees Of The University Of Pennsylvania MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTIONS AND SCREENING PROCEDURES FOR THIS
JP7460539B2 (ja) 2018-04-17 2024-04-02 ザ ジェネラル ホスピタル コーポレイション 核酸を結合、修飾、および切断する物質の基質選択性および部位のためのｉｎ ｖｉｔｒｏでの高感度アッセイ
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
CN109868285A (zh) * 2018-05-29 2019-06-11 江苏艾尔康生物医药科技有限公司 一种免疫缺陷大鼠动物模型的构建方法及应用
US10463029B1 (en) 2018-06-07 2019-11-05 Regeneron Pharmaceuticals, Inc. Rodent model of steel syndrome
WO2019241350A1 (en) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
PL3629720T3 (pl) 2018-06-14 2022-05-02 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek zdolne do rearanżacji dh-dh w sekwencjach kodujących łańcucha ciężkiego immunoglobuliny
EP3821012A4 (en) 2018-07-13 2022-04-20 The Regents of The University of California RETROTRANSPOSON-BASED DELIVERY VEHICLE AND METHOD OF USE THEREOF
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CA3109953A1 (en) * 2018-08-28 2020-03-05 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
CA3112612C (en) 2018-09-13 2024-02-27 Regeneron Pharmaceuticals, Inc. Complement factor h gene knockout rat as a model of c3 glomerulopathy
US11407995B1 (en) 2018-10-26 2022-08-09 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
US11434477B1 (en) 2018-11-02 2022-09-06 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
CN109504708A (zh) * 2018-12-03 2019-03-22 江苏集萃药康生物科技有限公司 一种筛选标记自我删除的基因打靶载体及方法
JP7449291B2 (ja) 2018-12-20 2024-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヌクレアーゼ媒介リピート伸長
MX2021008291A (es) 2019-01-17 2021-08-05 Regeneron Pharma Un modelo de roedor de trastornos del estado de animo.
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
US20220145330A1 (en) 2019-02-10 2022-05-12 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Modified mitochondrion and methods of use thereof
CN112400022B (zh) * 2019-02-18 2023-06-30 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
CA3131145A1 (en) * 2019-02-21 2020-08-27 Nemametrix Inc Monogenic or polygenic disease model organisms humanized with two or more genes
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
WO2020190621A1 (en) 2019-03-15 2020-09-24 Regeneron Pharmaceuticals, Inc. A loss of function rodent model of solute carrier 39 member 5
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
US11737435B2 (en) 2019-04-04 2023-08-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
JP2022534867A (ja) 2019-06-04 2022-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
BR112021023683A2 (pt) 2019-06-05 2022-02-01 Regeneron Pharma Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
AU2020289581A1 (en) 2019-06-07 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
CN114008193A (zh) 2019-06-27 2022-02-01 瑞泽恩制药公司 Tdp-43蛋白病的建模
AU2020358847A1 (en) 2019-10-03 2022-04-21 Regeneron Pharmaceuticals, Inc. A Crnn loss of function rodent model
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
CN114786479B (zh) * 2019-12-25 2023-12-15 江苏集萃药康生物科技股份有限公司 一种il-15人源化小鼠模型及其用途
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
US20230081547A1 (en) 2020-02-07 2023-03-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
EP4114173A1 (en) 2020-03-04 2023-01-11 Regeneron Pharmaceuticals, Inc. A rodent model of b4galt1-mediated functions
CN113355323B (zh) * 2020-03-06 2023-07-11 生物岛实验室 人源化ace2基因改造小鼠模型的制备方法及应用
CN113355325B (zh) * 2020-03-06 2023-07-14 中国科学院广州生物医药与健康研究院 人源化ace2基因改造小鼠胚胎干细胞模型制备方法及应用
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
JP2023523174A (ja) 2020-04-21 2023-06-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals Beijing Co Ltd GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
IL301493A (en) 2020-10-01 2023-05-01 Regeneron Pharma Rodent animals expressing human CR1
CN116802200A (zh) 2020-12-21 2023-09-22 瑞泽恩制药公司 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物
CN112852875B (zh) * 2021-02-26 2022-10-21 福建省立医院 示踪肿瘤T淋巴细胞浸润的CD3e转基因小鼠模型的构建方法
CN113229213B (zh) * 2021-05-14 2022-06-14 福州大学 通过近红外荧光探针标记血栓实现肺栓塞造模及无创定量检测的方法
AU2022343300A1 (en) 2021-09-10 2024-04-18 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
AU2022408167A1 (en) 2021-12-08 2024-06-06 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
US20230257432A1 (en) 2022-02-11 2023-08-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
WO2023212560A1 (en) 2022-04-26 2023-11-02 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2023235677A1 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
WO1997030151A1 (en) 1996-02-16 1997-08-21 The University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
WO2000039316A1 (en) * 1998-12-31 2000-07-06 The J. David Gladstone Institutes Transgenic rodents and rodent cell lines expressing hiv co-receptors
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
AU2982900A (en) 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2002057308A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
EP1581610A4 (en) 2002-09-05 2009-05-27 California Inst Of Techn USE OF CHIMERIC NUCLEASES TO STIMULATE GENE TARGETING
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
KR20060002745A (ko) 2003-01-13 2006-01-09 마헨드라 에스 라오 치료적 생성물의 전달을 위한 증식성 줄기세포 및전구세포에서의 후보 분자의 지속적 발현
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
KR20120091471A (ko) 2004-03-04 2012-08-17 도쿠리츠교세이호진 고쿠리츠간켄큐센터 래트 배아 줄기 세포
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
ES2364878T3 (es) 2004-09-03 2011-09-15 Moraga Biotechnology Inc. Células madre de tipo blastómero totipotenciales no embrionarias y procedimientos de las mismas.
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US7294754B2 (en) * 2004-10-19 2007-11-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
FR2879622B1 (fr) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
AU2006224248B2 (en) 2005-03-15 2011-01-06 Cellectis I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
WO2007113505A2 (en) * 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
EP3070169B1 (en) 2006-12-14 2018-05-09 Dow AgroSciences LLC Optimized non-canonical zinc finger proteins
US7771967B2 (en) * 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
ATE489465T1 (de) 2007-04-26 2010-12-15 Sangamo Biosciences Inc Gezielte integration in die ppp1r12c-position
US8703485B2 (en) 2007-06-01 2014-04-22 Omt, Inc. Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom
CA2734235C (en) 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2180058A1 (en) 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
CA2745031C (en) * 2008-12-04 2018-08-14 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
SG172160A1 (en) 2008-12-17 2011-07-28 Scripps Research Inst Generation and maintenance of stem cells
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
JP5932632B2 (ja) 2009-03-20 2016-06-15 サンガモ バイオサイエンシーズ， インコーポレイテッド 改変された亜鉛フィンガータンパク質を使用したｃｘｃｒ４の修飾
WO2010124200A2 (en) 2009-04-23 2010-10-28 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cancer
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
EP2456876A2 (en) 2009-07-24 2012-05-30 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cytokine-cytokine signaling pathways
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2011020014A1 (en) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
CA2779337A1 (en) 2009-10-28 2011-05-05 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) Homologous recombination in the oocyte
TR201903376T4 (tr) 2009-10-29 2019-04-22 Regeneron Pharma Çok fonksiyonlu alleller.
WO2011053957A2 (en) 2009-11-02 2011-05-05 Gen9, Inc. Compositions and methods for the regulation of multiple genes of interest in a cell
EP2508595B1 (en) 2009-12-01 2016-11-23 National Cancer Center Method for constructing chimeric rat using rat embryonic stem cells
CN106834320B (zh) 2009-12-10 2021-05-25 明尼苏达大学董事会 Tal效应子介导的dna修饰
CN102791865B (zh) 2009-12-21 2015-07-01 凯津公司 用于转染原生质体的改进技术
KR101951489B1 (ko) 2010-01-22 2019-04-22 다우 아그로사이언시즈 엘엘씨 유전적으로 변형된 유기체에서 도입유전자의 절제
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
EP2579711B1 (en) 2010-06-11 2019-04-17 Regeneron Pharmaceuticals, Inc. Production of fertile xy female animals from xy es cells
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
WO2012018726A1 (en) 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
WO2012129198A1 (en) * 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
WO2012168307A2 (en) 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Improved recombination efficiency by inhibition of nhej dna repair
US20140373187A1 (en) * 2011-08-26 2014-12-18 Yecuris Corporation Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
KR102148387B1 (ko) 2011-10-28 2020-08-26 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CN109536526B (zh) 2012-04-25 2020-06-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
DE102012103797A1 (de) * 2012-04-30 2013-10-31 KRAH Elektronische Bauelemente GmbH Flüssigkeitsgekühlter Widerstand
KR102116153B1 (ko) 2012-05-07 2020-05-27 상가모 테라퓨틱스, 인코포레이티드 도입유전자의 뉴클레아제-매개 표적화된 통합을 위한 방법 및 조성물
UA118014C2 (uk) 2012-05-25 2018-11-12 Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія Спосіб модифікації днк-мішені
WO2013188522A2 (en) 2012-06-12 2013-12-19 Genentech, Inc. Methods and compositions for generating conditional knock-out alleles
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
CN110669746B (zh) 2012-10-23 2024-04-16 基因工具股份有限公司 用于切割靶dna的组合物及其用途
IL300199A (en) 2012-12-06 2023-03-01 Sigma Aldrich Co Llc CRISPR-based genome modification and regulation
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
SG10201912327SA (en) 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
CA2894668A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
PL2921557T3 (pl) 2012-12-12 2017-03-31 Broad Inst Inc Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
ES2741951T3 (es) 2012-12-17 2020-02-12 Harvard College Modificación por ingeniería genética del genoma humano guiada por ARN
EP3491915B1 (en) 2012-12-27 2023-05-31 Keygene N.V. Method for inducing a targeted translocation in a plant.
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
ES2904803T3 (es) 2013-02-20 2022-04-06 Regeneron Pharma Modificación genética de ratas
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
JP2016507244A (ja) 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
AU2014235794A1 (en) 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
WO2014153470A2 (en) 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
CN105518146B (zh) 2013-04-04 2022-07-15 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
ES2699578T3 (es) 2013-04-16 2019-02-11 Regeneron Pharma Modificación direccionada del genoma de rata
US20160040155A1 (en) 2013-04-16 2016-02-11 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
EP2796558A1 (en) 2013-04-23 2014-10-29 Rheinische Friedrich-Wilhelms-Universität Bonn Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants
JP2016518142A (ja) 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
US9873894B2 (en) 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US20160122774A1 (en) 2013-05-29 2016-05-05 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
DK3309248T3 (da) 2013-05-29 2021-08-02 Cellectis Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
US20140359795A1 (en) 2013-05-31 2014-12-04 Recombinetics, Inc. Genetic techniques for making animals with sortable sperm
WO2014201015A2 (en) 2013-06-11 2014-12-18 The Regents Of The University Of California Methods and compositions for target dna modification
WO2014204729A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
JP6625971B2 (ja) 2013-06-17 2019-12-25 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
AU2014281030B2 (en) 2013-06-17 2020-07-09 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
CN113425857A (zh) 2013-06-17 2021-09-24 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
CN105555948A (zh) 2013-06-19 2016-05-04 西格马-奥尔德里奇有限责任公司 靶向整合
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
RU2764637C2 (ru) 2013-07-09 2022-01-19 Президент Энд Фэллоуз Оф Харвард Коллидж Мультиплексная геномная инженерия, направляемая рнк
AU2014287397B2 (en) 2013-07-10 2019-10-10 President And Fellows Of Harvard College Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
US9663782B2 (en) 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
WO2015026886A1 (en) 2013-08-22 2015-02-26 E. I. Du Pont De Nemours And Company Methods for producing genetic modifications in a plant genome without incorporating a selectable transgene marker, and compositions thereof
KR20160060659A (ko) 2013-08-29 2016-05-30 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150079680A1 (en) 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
CN110713995B (zh) 2013-10-17 2023-08-01 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
US20160264995A1 (en) 2013-11-06 2016-09-15 Hiroshima University Vector for Nucleic Acid Insertion
CN111218447A (zh) 2013-11-07 2020-06-02 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
EP3074515B1 (en) 2013-11-28 2018-11-14 Horizon Discovery Limited Somatic haploid human cell line
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
KR20160089526A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 입자 전달 성분을 이용한 표적 장애 및 질병에 대한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 이용 및 치료 적용
AU2014361784A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
SG10201804976YA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
KR20160097327A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CA2932436A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
CA2932948A1 (en) 2013-12-13 2015-06-18 Cellectis New method of selection of algal-transformed cells using nuclease
CA2933902C (en) 2013-12-19 2022-08-30 Amyris, Inc. Methods for genomic integration
SG11201605550QA (en) 2014-01-08 2016-08-30 Harvard College Rna-guided gene drives
CA2936976A1 (en) 2014-01-24 2015-07-30 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
WO2015117041A1 (en) 2014-01-30 2015-08-06 Nair Ramesh B Gene modification-mediated methods and compositions for generating dominant traits in eukaryotic systems
US10233456B2 (en) 2014-01-30 2019-03-19 The Board Of Trustees Of The University Of Arkansas Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
CA2938456C (en) 2014-02-11 2022-06-21 The Regents Of The University Of Colorado, A Body Corporate Crispr enabled multiplexed genome engineering
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
EP3114227B1 (en) 2014-03-05 2021-07-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
EP3116997B1 (en) 2014-03-10 2019-05-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
CA2942268A1 (en) 2014-03-12 2015-09-17 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
CN117867008A (zh) 2014-03-14 2024-04-12 希博斯美国有限公司 采用寡核苷酸介导的基因修复提高靶向基因修饰的效率的方法和组合物
EP3929279A1 (en) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US10349639B2 (en) 2014-03-26 2019-07-16 University Of Maryland, College Park Targeted genome editing in zygotes of domestic large animals
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
KR101823661B1 (ko) 2014-04-24 2018-01-30 기초과학연구원 마이크로 상동 기반의 유전자 녹아웃을 위한 뉴클레아제 표적 서열을 확인하는 방법
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015173436A1 (en) 2014-05-16 2015-11-19 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
US20160060655A1 (en) 2014-05-30 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
LT3152312T (lt) 2014-06-06 2020-04-27 Regeneron Pharmaceuticals, Inc. Tikslinio lokuso modifikavimo būdai ir kompozicijos
CA2952697A1 (en) 2014-06-16 2015-12-23 The Johns Hopkins University Compositions and methods for the expression of crispr guide rnas using the h1 promoter
PL3161128T3 (pl) 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do celowanych modyfikacji genetycznych i sposoby zastosowania
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3193944B1 (en) 2014-07-17 2021-04-07 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating cells containing fusion genes
US9944933B2 (en) 2014-07-17 2018-04-17 Georgia Tech Research Corporation Aptamer-guided gene targeting
WO2016033246A1 (en) 2014-08-27 2016-03-03 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
EP3778891A1 (en) 2014-08-27 2021-02-17 New England Biolabs, Inc. Synthon formation
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
KR20170045344A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
JP2017534295A (ja) 2014-09-29 2017-11-24 ザ ジャクソン ラボラトリー エレクトロポレーションによる遺伝子改変哺乳動物の高効率ハイスループット生成
WO2016054326A1 (en) 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
US20180250424A1 (en) 2014-10-10 2018-09-06 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016061073A1 (en) 2014-10-14 2016-04-21 Memorial Sloan-Kettering Cancer Center Composition and method for in vivo engineering of chromosomal rearrangements
AU2015332451A1 (en) 2014-10-15 2017-04-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
EP3207139A1 (en) 2014-10-17 2017-08-23 The Penn State Research Foundation Methods and compositions for multiplex rna guided genome editing and other rna technologies
EP3207131B1 (en) 2014-10-17 2022-09-28 Howard Hughes Medical Institute Genomic probes
WO2016065364A1 (en) 2014-10-24 2016-04-28 Life Technologies Corporation Compositions and methods for enhancing homologous recombination
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
US10457960B2 (en) 2014-11-21 2019-10-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
EP3224363B1 (en) 2014-11-27 2021-11-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid constructs for genome editing
WO2016089866A1 (en) 2014-12-01 2016-06-09 President And Fellows Of Harvard College Rna-guided systems for in vivo gene editing
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
MX2017008190A (es) 2014-12-19 2018-03-23 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins
US10280451B2 (en) 2015-01-09 2019-05-07 Bio-Rad Laboratories, Inc. Detection of genome editing
US11208638B2 (en) 2015-01-12 2021-12-28 The Regents Of The University Of California Heterodimeric Cas9 and methods of use thereof
WO2016115326A1 (en) 2015-01-15 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating genome editing
KR102319192B1 (ko) 2015-01-28 2021-10-28 카리부 바이오사이언시스 인코포레이티드 Crispr 하이브리드 dna/rna 폴리뉴클레오티드 및 사용 방법
WO2016130697A1 (en) 2015-02-11 2016-08-18 Memorial Sloan Kettering Cancer Center Methods and kits for generating vectors that co-express multiple target molecules
BR112017017812A2 (pt) 2015-02-23 2018-04-10 Crispr Therapeutics Ag materiais e métodos para tratamento de hemoglobinopatias
US20180200387A1 (en) 2015-02-23 2018-07-19 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
WO2016138574A1 (en) 2015-03-02 2016-09-09 Sinai Health System Homologous recombination factors
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
EP3274453B1 (en) 2015-03-26 2021-01-27 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Also Published As

Publication number Publication date
CN105308184B (zh) 2020-06-02
AU2020233694A1 (en) 2020-10-08
CN105308184A (zh) 2016-02-03
PL2986729T3 (pl) 2019-04-30
CY1120845T1 (el) 2019-12-11
IL241856B (en) 2020-09-30
US20170204430A1 (en) 2017-07-20
MY177850A (en) 2020-09-23
HUE040575T2 (hu) 2019-03-28
KR20150141987A (ko) 2015-12-21
HRP20181648T1 (hr) 2019-01-25
SI2986729T1 (sl) 2019-02-28
PT3456831T (pt) 2021-09-10
SI3456831T1 (sl) 2021-11-30
CN111500630A (zh) 2020-08-07
EP3456831A1 (en) 2019-03-20
EP2986729A4 (en) 2016-10-19
NZ713343A (en) 2021-08-27
DK3456831T3 (da) 2021-09-06
WO2014172489A3 (en) 2014-12-11
DK2986729T3 (en) 2018-10-29
PL3456831T3 (pl) 2021-12-06
HRP20211385T1 (hr) 2021-12-10
EP2986729B1 (en) 2018-09-19
BR112015026197B1 (pt) 2022-12-06
JP2016515401A (ja) 2016-05-30
EP3456831B1 (en) 2021-07-14
EP2986729A2 (en) 2016-02-24
US20140309487A1 (en) 2014-10-16
RU2676708C2 (ru) 2019-01-10
US10385359B2 (en) 2019-08-20
US20210301301A1 (en) 2021-09-30
SG11201508028QA (en) 2015-10-29
ES2888250T3 (es) 2022-01-03
CY1124627T1 (el) 2022-07-22
HUE056903T2 (hu) 2022-04-28
WO2014172489A2 (en) 2014-10-23
MX2015014487A (es) 2016-07-28
MX369747B (es) 2019-11-20
IL276772A (en) 2020-10-29
LT2986729T (lt) 2018-10-25
AU2014253942A1 (en) 2015-11-12
ES2699578T3 (es) 2019-02-11
CA2908697A1 (en) 2014-10-23
AU2014253942B2 (en) 2020-07-02
BR112015026197A2 (pt) 2017-10-10
CA2908697C (en) 2023-12-12
HK1214625A1 (zh) 2016-07-29
US20190323032A1 (en) 2019-10-24
RS62263B1 (sr) 2021-09-30
US10975390B2 (en) 2021-04-13
JP6411463B2 (ja) 2018-10-24
KR20200136508A (ko) 2020-12-07
KR102186281B1 (ko) 2020-12-03
AU2014253942B9 (en) 2020-08-13
PT2986729T (pt) 2018-11-30
RU2015148637A (ru) 2017-05-22
HRP20211385T8 (hr) 2022-03-04
LT3456831T (lt) 2021-09-10
US20140310828A1 (en) 2014-10-16
SG10201808935WA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
HRP20211385T8 (hr) Ciljana modifikacija genoma štakora
IL272193B (en) Genome engineering
HK1214627A1 (zh) 大鼠的遺傳修飾
IL245674A0 (en) Methods and preparations for the targeted modification of a genome
EP3004433A4 (en) SUBSTANTIALLY EVEN AMPLIFICATION OF GENOME
HK1202053A1 (en) Treatment of liver conditions
EP2903643A4 (en) TREATMENT OF PSYCHIATRIC DISEASES
HRP20181632T1 (hr) Postupci i kompoziti za ciljanu modificiranje genoma
IL233740A0 (en) Treatment of liver diseases
HK1198422A1 (en) Novel uses of colossolactones
HK1170114A2 (en) One type of range hood
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling
GB201304608D0 (en) BenTime of Yisrael operable arrangement